Related Experiment Video

Updated: Aug 22, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor

Eiji Suzuki1, Veena Kapoor, H Kam Cheung

  • 1Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 10, 2004
PubMed
Abstract

Insights

Transforming growth factor-beta (TGF-beta) blockade effectively inhibited malignant mesothelioma (MM) tumor growth in mice. This therapy shows promise for MM and other TGF-beta-producing tumors, primarily through immune-mediated responses.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapy

Background:

  • Malignant mesothelioma (MM) is a lethal, treatment-resistant cancer.
  • Transforming growth factor-beta (TGF-beta) blockade is a potential anticancer strategy.
  • MM produces significant amounts of TGF-beta, making it a potential target.

Purpose of the Study:

  • To investigate the therapeutic potential of TGF-beta blockade in malignant mesothelioma.
  • To determine if blocking TGF-beta can inhibit MM tumor growth.

Main Methods:

  • Tested a soluble TGF-beta type II receptor (sTGF-beta R) in three murine MM models.
  • Models included TGF-beta-producing (AB12, AC29) and non-producing (AB1) tumors.
  • Evaluated effects in immunocompetent and immunodeficient mice.

Main Results:

  • sTGF-beta R inhibited growth of established AB12 and AC29 tumors.
  • AB1 tumors, which do not produce TGF-beta, showed minimal response.
  • Antitumor effects were dependent on CD8(+) T cells and immune responses.

Conclusions:

  • TGF-beta blockade is a promising strategy for established TGF-beta-secreting MM.
  • This approach may also benefit other TGF-beta-producing tumors.
  • Immune-mediated mechanisms are key to TGF-beta blockade's efficacy.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.